BRIEF-Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases

Reuters02-25

BRIEF-<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases

Feb 24 (Reuters) - Hoth Therapeutics Inc HOTH.O:

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
HOTH THERAPEUTICS INC - 100% OF COHORT PATIENTS ACHIEVED PRIMARY EFFICACY ENDPOINT IN INTERIM CLEER-001 DATA
HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED REDUCTIONS IN PAIN AND ITCHING
HOTH THERAPEUTICS INC - ZERO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION

Source text: ID:nPn3Df7y0a

Further company coverage: HOTH.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614729160?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614729160","market":"fut","top_or_hot":-1,"title":"BRIEF-Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HOTH.O</span>:</p><ul><li><p>HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES</p></li><li><p>HOTH THERAPEUTICS INC - 100% OF <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> PATIENTS ACHIEVED PRIMARY EFFICACY ENDPOINT IN INTERIM CLEER-001 DATA</p></li><li><p>HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED REDUCTIONS IN PAIN AND ITCHING</p></li><li><p>HOTH THERAPEUTICS INC - ZERO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION</p></li></ul><p>Source text: <span>ID:nPn3Df7y0a</span></p><p>Further company coverage: <span>HOTH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 06:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HOTH.O</span>:</p><ul><li><p>HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES</p></li><li><p>HOTH THERAPEUTICS INC - 100% OF <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> PATIENTS ACHIEVED PRIMARY EFFICACY ENDPOINT IN INTERIM CLEER-001 DATA</p></li><li><p>HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED REDUCTIONS IN PAIN AND ITCHING</p></li><li><p>HOTH THERAPEUTICS INC - ZERO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION</p></li></ul><p>Source text: <span>ID:nPn3Df7y0a</span></p><p>Further company coverage: <span>HOTH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOTH","symbol_name":"Hoth Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA3GTTHQ:1","article_id":"2614729160","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614729160","pubTimestamp":1771973506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand IncreasesFeb 24 (Reuters) - Hoth Therapeutics Inc HOTH.O:HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOTH":"Hoth Therapeutics","BK4007":"制药"},"translate_title":"简介-随着患者需求的增加，Hoth Therapeutics通过新的临床站点加速HT-001试验招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"BRIEF-Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand IncreasesFeb 24 (Reuters) - Hoth Therapeutics Inc HOTH.O:HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASESHOTH THERAPEUTICS INC - 100% OF COHORT PATIENTS ACHIEVED PRIMARY EFFICACY ENDPOINT IN INTERIM CLEER-001 DATAHOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED REDUCTIONS IN PAIN AND ITCHINGHOTH THERAPEUTICS INC - ZERO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATIONSource text: ID:nPn3Df7y0aFurther company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614729160","isCrawlerRequest":true}